Norman Relkin, Ph.D., M.D
Alzheimer’s Disease Advisory Board
Norman Relkin, is an ABPN board-certified Neurologist who graduated from Yale College and received his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine. He has been a physician at the New York Presbyterian Hospital - Weill Cornell Medical Center since 1987 and Director of the Cornell Memory Disorders Program since 1993. Dr. Relkin is internationally recognized for his work on Alzheimer's Disease and related disorders. He is the author of a book, several book chapters and numerous scientific papers on neurodegenerative and traumatic disorders of the brain, and lectures throughout the world on these topics. | Lindsay Farrer, PhD
Alzheimer’s Disease Advisory Board
Dr. Lindsay Farrer is a medical geneticist at Boston University School of Medicine and Public Health where he is Chief of the Genetics Program, Director of the Genetic Epidemiology Center, and a Professor of Medicine, Neurology, Genetics & Genomics, Epidemiology, and Biostatistics. Dr. Farrer is a graduate of the University of North Carolina in Chapel Hill, received his Ph.D. from the Indiana University School of Medicine, and gained additional training in genetic epidemiology at Yale University. He holds adjunct faculty positions at Harvard Medical School, Massachusetts General Hospital, and the Veterans Administration Medical Center in Bedford, Massachusetts. He is a Founding Fellow of the American College of Medical Genetics. Dr. Farrer teaches several courses in human genetics and genetic epidemiology at Boston University, directs the Molecular Genetics Core Facility, which offers DNA genotyping and sequencing services to investigators at the Boston Medical Center, and provides genetic counseling and testing to patients with a variety of inherited conditions. | W. Andrew (Andy) Faucett M.S., C.G.C
Genetic Counseling Advisor
W. Andrew Faucett has worked as a genetic counselor and public health geneticist since 1987. He has provided prenatal and cancer genetic counseling services; developed healthcare provider education; and recently has focused on rare disease test translation, oversight and education. Andy is a faculty member in the Department of Human Genetics at Emory University School of Medicine, CETT Program Coordinator for the NIH Office of Rare Diseases, and has an Interagency Professional Agreement with the Centers for Disease Control and Prevention (CDC) to work on genetic testing issues. Andy received his B.S. from the Baptist College at Charleston and his M.S. in genetic counseling from Sarah Lawrence College. He is board certified by the American Board of Genetic Counseling (ABGC). He worked in Houston and Savannah, Georgia prior to moving to Atlanta to work with the CDC and Emory. He is an active leader in the profession of genetic counseling and has served on the Board of Directors for the National Society of Genetic Counselors (NSGC), the ABGC, and the Jane Engelberg Memorial Fellowship. | Howard McLeod, Pharm.D.
Scientific Advisor
Dr. Howard McLeod is a Fred N. Eshelman Distinguished Professor and Director of the UNC Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina Chapel Hill School of Pharmacy. He received his Doctor of Pharmacy from Philadelphia College of Pharmacy and Science and went on to complete research fellowship training in cancer pharmacology at St. Jude Children's Research Hospital in Memphis and at the University of Glasgow in Scotland. Dr. McLeod is an internationally recognized expert in the pharmacogenomic analysis of cancer therapeutics and is a member of the FDA Subcommittee on Clinical Pharmacology. |
|
